CORDIS
EU research results

CORDIS

English EN
Next Generation Microbiome Platform

Next Generation Microbiome Platform

Objective

PharmaBiome AG is an ETH Zurich spin-off company that was established in February 2015 after intense scientific interactions at ETH Zurich between highly qualified scientists and business professionals in the fields of biotechnology and gastroenterology. We envisioned a huge interest of the pharmaceutical industry in microbiome-based technologies.

Our primary target market focuses on patients suffering from recurrent Clostridium difficile infections (rCDI), which are usually a consequence of antibiotic use. Almost 900.000 cases of CDI in the EU and USA may occur each year bringing the acute-care direct costs of CDI to an estimated 4.5 billion € in 2008. The treatment consists of intestinal communities from faeces of healthy donors (Faecal Microbiota Therapy, FMT). However, FMT is not standardized as the contents that are present in the human stool vary from individual to individual and change over time. Moreover, there are safety concerns associated with FMT such as the transmission of the pathogenic microbes from improperly screened and handled stool. FMT is also associated with the need for a healthy donor in every case.

FlexiBiome will bring to the market a standardized therapeutic mixture of living intestinal bacteria as an alternative to FMT. Our innovation represents a safe (of a defined composition, clear mode of action), efficient (same functionality as FMT but using a controlled delivery), flexible (production is controlled, the product is storable and we will provide access to large markets) and targeted therapeutic to fight rCDI. Flexibiome will be 50 % cheaper than FMT therapy.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

PHARMABIOME AG

Address

Schmelzbergstrasse 7
8092 Zurich

Switzerland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 807302

Status

Closed project

  • Start date

    1 April 2018

  • End date

    31 July 2018

Funded under:

H2020-EU.2.1.4.

H2020-EU.2.3.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

PHARMABIOME AG

Switzerland